Werewolf Therapeutics Inc
NASDAQ:HOWL

Watchlist Manager
Werewolf Therapeutics Inc Logo
Werewolf Therapeutics Inc
NASDAQ:HOWL
Watchlist
Price: 2 USD 5.26%
Market Cap: 89.1m USD
Have any thoughts about
Werewolf Therapeutics Inc?
Write Note

Intrinsic Value

HOWL's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one HOWL stock under the Base Case scenario is 1.5 USD. Compared to the current market price of 2 USD, Werewolf Therapeutics Inc is Overvalued by 25%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

HOWL Intrinsic Value
1.5 USD
Overvaluation 25%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Werewolf Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for HOWL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about HOWL?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Werewolf Therapeutics Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Werewolf Therapeutics Inc

Provide an overview of the primary business activities
of Werewolf Therapeutics Inc.

What unique competitive advantages
does Werewolf Therapeutics Inc hold over its rivals?

What risks and challenges
does Werewolf Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Werewolf Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Werewolf Therapeutics Inc.

Provide P/S
for Werewolf Therapeutics Inc.

Provide P/E
for Werewolf Therapeutics Inc.

Provide P/OCF
for Werewolf Therapeutics Inc.

Provide P/FCFE
for Werewolf Therapeutics Inc.

Provide P/B
for Werewolf Therapeutics Inc.

Provide EV/S
for Werewolf Therapeutics Inc.

Provide EV/GP
for Werewolf Therapeutics Inc.

Provide EV/EBITDA
for Werewolf Therapeutics Inc.

Provide EV/EBIT
for Werewolf Therapeutics Inc.

Provide EV/OCF
for Werewolf Therapeutics Inc.

Provide EV/FCFF
for Werewolf Therapeutics Inc.

Provide EV/IC
for Werewolf Therapeutics Inc.

Show me price targets
for Werewolf Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Werewolf Therapeutics Inc?

How accurate were the past Revenue estimates
for Werewolf Therapeutics Inc?

What are the Net Income projections
for Werewolf Therapeutics Inc?

How accurate were the past Net Income estimates
for Werewolf Therapeutics Inc?

What are the EPS projections
for Werewolf Therapeutics Inc?

How accurate were the past EPS estimates
for Werewolf Therapeutics Inc?

What are the EBIT projections
for Werewolf Therapeutics Inc?

How accurate were the past EBIT estimates
for Werewolf Therapeutics Inc?

Compare the revenue forecasts
for Werewolf Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Werewolf Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Werewolf Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Werewolf Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Werewolf Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Werewolf Therapeutics Inc with its peers.

Analyze the financial leverage
of Werewolf Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Werewolf Therapeutics Inc.

Provide ROE
for Werewolf Therapeutics Inc.

Provide ROA
for Werewolf Therapeutics Inc.

Provide ROIC
for Werewolf Therapeutics Inc.

Provide ROCE
for Werewolf Therapeutics Inc.

Provide Gross Margin
for Werewolf Therapeutics Inc.

Provide Operating Margin
for Werewolf Therapeutics Inc.

Provide Net Margin
for Werewolf Therapeutics Inc.

Provide FCF Margin
for Werewolf Therapeutics Inc.

Show all solvency ratios
for Werewolf Therapeutics Inc.

Provide D/E Ratio
for Werewolf Therapeutics Inc.

Provide D/A Ratio
for Werewolf Therapeutics Inc.

Provide Interest Coverage Ratio
for Werewolf Therapeutics Inc.

Provide Altman Z-Score Ratio
for Werewolf Therapeutics Inc.

Provide Quick Ratio
for Werewolf Therapeutics Inc.

Provide Current Ratio
for Werewolf Therapeutics Inc.

Provide Cash Ratio
for Werewolf Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Werewolf Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Werewolf Therapeutics Inc?

What is the current Free Cash Flow
of Werewolf Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Werewolf Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Werewolf Therapeutics Inc

Current Assets 125.8m
Cash & Short-Term Investments 122.8m
Receivables 464k
Other Current Assets 2.5m
Non-Current Assets 14.2m
PP&E 12.9m
Other Non-Current Assets 1.3m
Current Liabilities 12.5m
Accounts Payable 1.2m
Accrued Liabilities 11.2m
Non-Current Liabilities 38.2m
Long-Term Debt 25.6m
Other Non-Current Liabilities 12.6m
Efficiency

Earnings Waterfall
Werewolf Therapeutics Inc

Revenue
3.4m USD
Operating Expenses
-69.6m USD
Operating Income
-66.2m USD
Other Expenses
4.1m USD
Net Income
-62.1m USD

Free Cash Flow Analysis
Werewolf Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

HOWL Profitability Score
Profitability Due Diligence

Werewolf Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

ROE is Increasing
ROIC is Increasing
Negative 1-Year Revenue Growth
Negative Revenue Growth Forecast
19/100
Profitability
Score

Werewolf Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

HOWL Solvency Score
Solvency Due Diligence

Werewolf Therapeutics Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
51/100
Solvency
Score

Werewolf Therapeutics Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

HOWL Price Targets Summary
Werewolf Therapeutics Inc

Wall Street analysts forecast HOWL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HOWL is 12.24 USD with a low forecast of 8.08 USD and a high forecast of 15.75 USD.

Lowest
Price Target
8.08 USD
304% Upside
Average
Price Target
12.24 USD
512% Upside
Highest
Price Target
15.75 USD
688% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for HOWL?

Click here to dive deeper.

Dividends

Werewolf Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for HOWL is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

HOWL Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Werewolf Therapeutics Inc Logo
Werewolf Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

87.4m USD

Dividend Yield

0%

Description

Werewolf Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 39 full-time employees. The company went IPO on 2021-04-30. The firm is focused on developing a pipeline of cancer treatments. The company is developing immuno-stimulatory therapeutics designed to act selectively within the tumor microenvironment to enhance the body’s immune response to cancer. Its PREDATOR platform is designed to conditionally activate molecules that stimulate both adaptive and innate immunity while addressing the limitations of conventional proinflammatory immune therapies. The INDUKINETM molecules, are intended to selectively target the tumor microenvironment (TME). PREDATOR platform consists of protein engineering technologies which are used to generate INDUKINE molecules with multiple functional domains rationally engineered into a single protein to achieve the pharmaceutical profile. The firm using PREDATOR platform, has developed three initial product candidates: WTX-124, WTX-330 and WTX-613.

Contact

MASSACHUSETTS
Cambridge
1030 Massachusetts Avenue, Suite 210
+16179520555.0
werewolftx.com

IPO

2021-04-30

Employees

39

Officers

Founder, CEO, President, Secretary & Director
Dr. Daniel J. Hicklin Ph.D.
CFO, Treasurer & Assistant Secretary
Mr. Timothy W. Trost CPA
Chief Medical Officer
Dr. Randi Isaacs M.D.
Senior Vice President of Research
Dr. William Winston Ph.D.
Chief Technology Officer
Dr. Chulani Karunatilake Ph.D.
Chief Business Officer
Ms. Ellen A. Lubman M.B.A.

See Also

Discover More
What is the Intrinsic Value of one HOWL stock?

The intrinsic value of one HOWL stock under the Base Case scenario is 1.5 USD.

Is HOWL stock undervalued or overvalued?

Compared to the current market price of 2 USD, Werewolf Therapeutics Inc is Overvalued by 25%.

Back to Top